Finance Director Jeremy Sturgess-Smith introduces Ananda Developments, outlining the company’s mission, strategic focus, and what makes it distinct within the CBD and drug development sectors.
Jeremy highlights the key takeaways for investors, including Ananda’s focus on CBD for inflammatory pain conditions that set it apart from traditional CBD companies.
He also provides an overview of the competitive landscape, explaining how Ananda’s scientific approach to drug development places it in a unique position to capitalise on emerging opportunities. The episode was recorded prior to announcing the Epilepsy Trials’ shared on the 21st of October.
This introductory episode is part of Ananda’s commitment to fostering a closer, more transparent relationship with investors by sharing direct insights from the leadership team. Designed to provide context around the company’s mission and differentiators, the series invites investors to engage with Ananda, submit questions, and be part of an informed community.
UK-based biotech company Ananda Developments has strengthened its reputation as a leader in clinical cannabis research in Europe by announcing the launch of two significant new trials using its proprietary compounds.
Last month, Business of Cannabis reported that two long-awaited NHS clinical trials, aimed at exploring the potential of cannabis-based medicines for severe epilepsy, were finally set to begin—nearly six years after being initially promised.
Subsequent reports confirmed that Ananda Developments had secured a competitive tender to participate in these groundbreaking trials, which are the most extensive studies to date on cannabis and refractory epilepsy.
These Phase III trials mark the latest in a series of pioneering research initiatives in the UK and beyond, leveraging compounds developed by Ananda.
Ananda’s CEO Melissa Sturgess told Business of Cannabis: “Our approach has been to ask, ‘What are regulators like the MHRA and NICE asking for? How can we meet those requirements?’ … It’s about meeting regulators at their point of need, rather than debating how they should regulate the space.”
